Igm Biosciences Stock Buy Hold or Sell Recommendation
| IGMS Stock | USD 10.43 0.97 10.25% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding IGM Biosciences is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell IGM Biosciences given historical horizon and risk tolerance towards IGM Biosciences. When Macroaxis issues a 'buy' or 'sell' recommendation for IGM Biosciences, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out IGM Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy IGM Stock please use our How to Invest in IGM Biosciences guide. Note, we conduct extensive research on individual companies such as IGM and provide practical buy, sell, or hold advice based on investors' constraints. IGM Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
IGM |
Execute IGM Biosciences Buy or Sell Advice
The IGM recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on IGM Biosciences. Macroaxis does not own or have any residual interests in IGM Biosciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute IGM Biosciences' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
IGM Biosciences Trading Alerts and Improvement Suggestions
| IGM Biosciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.13 M. Net Loss for the year was (246.42 M) with profit before overhead, payroll, taxes, and interest of 1.07 M. | |
| IGM Biosciences currently holds about 469.14 M in cash with (192.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| IGM Biosciences has a poor financial position based on the latest SEC disclosures | |
| Roughly 64.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Brokerages Set IGM Biosciences, Inc. PT at 16.13 |
IGM Biosciences Returns Distribution Density
The distribution of IGM Biosciences' historical returns is an attempt to chart the uncertainty of IGM Biosciences' future price movements. The chart of the probability distribution of IGM Biosciences daily returns describes the distribution of returns around its average expected value. We use IGM Biosciences price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of IGM Biosciences returns is essential to provide solid investment advice for IGM Biosciences.
| Mean Return | 0.29 | Value At Risk | -9.42 | Potential Upside | 11.62 | Standard Deviation | 7.39 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of IGM Biosciences historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
IGM Stock Institutional Investors
The IGM Biosciences' institutional investors refer to entities that pool money to purchase IGM Biosciences' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 223 K | Northern Trust Corp | 2024-09-30 | 191.7 K | Rhenman Partners Asset Management Ab | 2024-09-30 | 185.5 K | Td Asset Management Inc | 2024-09-30 | 164.5 K | Charles Schwab Investment Management Inc | 2024-09-30 | 148.4 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 107.3 K | Bruce & Co Inc | 2024-09-30 | 100 K | D. E. Shaw & Co Lp | 2024-09-30 | 97.7 K | Woodline Partners Lp | 2024-06-30 | 75 K | Baker Bros Advisors Lp | 2024-09-30 | 4.1 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 4.1 M |
IGM Biosciences Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (203.2M) | 57.7M | 28.1M | (225.6M) | 64.2M | 67.4M | |
| Change In Cash | 33.9M | 205.2M | (107.0M) | (12.1M) | (8.8M) | (8.4M) | |
| Free Cash Flow | (47.5M) | (84.8M) | (137.6M) | (16.1M) | (204.6M) | (194.4M) | |
| Depreciation | 597K | 1.0M | 4.5M | 6.1M | 8.3M | 8.7M | |
| Capital Expenditures | 2.3M | 17.5M | 13.2M | 10.2M | 12.4M | 8.9M | |
| Net Income | (43.1M) | (81.4M) | (165.2M) | (221.1M) | (246.4M) | (234.1M) | |
| End Period Cash Flow | 35.9M | 241.1M | 134.0M | 121.9M | 113.1M | 101.9M | |
| Change To Netincome | 2.4M | 11.0M | 25.7M | 54.0M | 62.1M | 65.2M | |
| Other Non Cash Items | 1.7M | 2.6M | 3.2M | 9.3M | 6.1M | 4.2M |
IGM Biosciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to IGM Biosciences or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that IGM Biosciences' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a IGM stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.05 | |
β | Beta against Dow Jones | 2.02 | |
σ | Overall volatility | 7.48 | |
Ir | Information ratio | 0.02 |
IGM Biosciences Volatility Alert
IGM Biosciences is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure IGM Biosciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact IGM Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.IGM Biosciences Fundamentals Vs Peers
Comparing IGM Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze IGM Biosciences' direct or indirect competition across all of the common fundamentals between IGM Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as IGM Biosciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of IGM Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing IGM Biosciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare IGM Biosciences to competition |
| Fundamentals | IGM Biosciences | Peer Average |
| Return On Equity | -1.32 | -0.31 |
| Return On Asset | -0.37 | -0.14 |
| Operating Margin | (124.78) % | (5.51) % |
| Current Valuation | 389.6 M | 16.62 B |
| Shares Outstanding | 34.08 M | 571.82 M |
| Shares Owned By Insiders | 35.04 % | 10.09 % |
| Shares Owned By Institutions | 63.98 % | 39.21 % |
| Number Of Shares Shorted | 2.84 M | 4.71 M |
| Price To Earning | (7.72) X | 28.72 X |
| Price To Book | 7.13 X | 9.51 X |
| Price To Sales | 212.55 X | 11.42 X |
| Revenue | 2.13 M | 9.43 B |
| Gross Profit | 1.07 M | 27.38 B |
| EBITDA | (253.36 M) | 3.9 B |
| Net Income | (246.42 M) | 570.98 M |
| Cash And Equivalents | 469.14 M | 2.7 B |
| Cash Per Share | 10.95 X | 5.01 X |
| Total Debt | 40.51 M | 5.32 B |
| Debt To Equity | 0.09 % | 48.70 % |
| Current Ratio | 10.79 X | 2.16 X |
| Book Value Per Share | 1.33 X | 1.93 K |
| Cash Flow From Operations | (192.23 M) | 971.22 M |
| Short Ratio | 11.97 X | 4.00 X |
| Earnings Per Share | (3.61) X | 3.12 X |
| Target Price | 19.6 | |
| Number Of Employees | 198 | 18.84 K |
| Beta | 0.19 | -0.15 |
| Market Capitalization | 620.21 M | 19.03 B |
| Total Asset | 423.41 M | 29.47 B |
| Retained Earnings | (821.24 M) | 9.33 B |
| Working Capital | 305.12 M | 1.48 B |
| Current Asset | 1.23 M | 9.34 B |
| Current Liabilities | 3.37 M | 7.9 B |
Note: Acquisition by Misbah Tahir of 66667 shares of IGM Biosciences subject to Rule 16b-3 [view details]
IGM Biosciences Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as IGM . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About IGM Biosciences Buy or Sell Advice
When is the right time to buy or sell IGM Biosciences? Buying financial instruments such as IGM Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having IGM Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Synthetics Thematic Idea Now
Synthetics
Companies involved in production of silicon and other synthetic products . The Synthetics theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Synthetics Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.